Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1,2-Diphenyl-1- butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells

Journal of Medicinal Chemistry

Volumn 42, Issue 16, 1999, Pages 3126-3133

  Kraft, Kelly S ^a   Ruenitz, Peter C ^a   Bartlett, Michael G ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (1,2 DIPHENYL 1 BUTENYL)PHENOXY] N,N DIMETHYLETHYLAMINE; ANTIESTROGEN; CARBOXYLIC ACID; ESTROGEN RECEPTOR; GLYCOLIC ACID DERIVATIVE; HYDROXYL GROUP; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DRUG EFFICACY; DRUG POTENCY; ESTROGEN BLOOD LEVEL; LIGAND BINDING; RECEPTOR AFFINITY;

ANTINEOPLASTIC AGENTS; CELL DIVISION; ESTROGEN ANTAGONISTS; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0033549901     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990078u     Document Type: Article

References (40)

1. (a) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The Medicinal Chemistry of Nonsteroidal Antiestrogena: a Review. Curr. Med. Chem. 1994, 1, 61-104.
2. (b) Jordan, V. C. Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer. Annu. Rev. Pharmacol. 1995, 35, 195-211.
3. (a) Love, R. R.; Mazese, R. B.; Tormey, D. C.; Barden, H. S.; Newcomb, P. A.; Jordan, V. C. Bone Mineral Density in Women with Breast Cancer Treated with Adjuvant Tamoxifen for at Least Two Years. Breast Cancer Res. Treat. 1988, 12, 297-302.
4. (b) Fornander, T.; Rutqvist, L. E.; Sjoberg, H. E.; Blomqvist, L.; Mattsson, A.; Glas, U. Long Term Adjuvant Tamoxifen in Early Breast Cancer: Effect on Bone Mineral Density in Postmenopausal Women. J. Clin. Oncol. 1990, 8, 1019-1024.
5. (a) Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. Tripartite Steroid Hormone Pharmacology: Interaction with Multiple Effector Sites as a Basis for the Cell-and Promoter-Specific Action of These Hormones. Mol. Endocrinol. 1996, 10, 119-131.
6. (b) Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Molecular Determinants of Tissue Selectivity in Estrogen-Receptor Modulators. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14105-14110.
7. (a) Grese, T. A.; Cho, S.; Finley, D. R.; Godfrey, A. G.; Jones, C. D.; Lugar III, C. W.; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Modifications of the 2-Arylbenzothiophene Core of Raloxifene. J. Med. Chem. 1997, 40, 146-167.
8. (b) Roos, W.; Oeze, L.; Loser, R.; Eppenberger, U. Antiestrogenic action of 3-Hydroxytamoxifen in the Human Breast Cancer Cell Line MCF-7. J. Natl. Canter Inst. 1983, 71, 55-59.
9. (c) Ke, H. Z.; Simmons, H. A.; Pirie, C. M.; Crawford, D. T.; Thompson, D. D. Droloxifene, a New Estrogen Antagonist/ Agonist, Prevents Bone Loss in Ovariectomized Rats. Endocrinology (Baltimore) 1995, 736, 2435-2441.
10. (d) Rosati, R. L.; DaSilva-Jardine, P.; Cameron, K. O.; Thompson, D. D.; Ke, H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. R.; Elliott, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pirie, C. M.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/ Antagonist, CP-336,156, a Diaryltetrahydronaphthalene. J. Med. Chem. 1998, 41, 2928-2931.
11. (e) Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. Discovery and Synthesis of [6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo-[b] thiophene - a Novel, Highly Potent, Selective Estrogen-Receptor Modulator. J. Med. Chem. 1997, 40, 1407-1416.
12. (f) Sato, M.; Turner, C. H.; Wang, T. Y.; Adrian, M. D.; Rowley, E.; Bryant, H. U. LY353381.HCl: A Novel Raloxifene Analogue with Improved SERM Potency and Efficacy in Vivo. J. Pharmacol. Exp. Ther. 1998, 287, 1-7.
13. (g) Gauthier, S.; Caron, B.; Cloutier, J.; Dory, Y. L.; Favre, A.; Larouche, D.; Mailhot, J.; Quellet, C.; Schwerdtfeger, A.; Leblanc, G.; Martel, C.; Simard, J.; Mérand, Y.; Bélanger, A.; Labrie, C.; Labrie, F. (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl-2,2-dimethylpropanoate (EM-800) - a Highly Potent, Specific, and Orally-Active Nonsteroidal Antiestrogen. J. Med. Chem. 1997, 40, 2117-2122.
14. (a) Willson, T. M.; Henke, B. R.; Momtahen, T. M.; Charifson, P. S.; Batchelor, K. W.; Lubahn, D. B.; Moore, L. B.; Oliver, B. B.; Sauls, H. R.; Triantafillou, J. A.; Wolfe, S. G.; Baer, P. G. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a Nonsteroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats. J. Med. Chem. 1994, 37, 1550-1552.
15. (b) Willson, T. M.; Norris, J. D.; Wagner, B. L.; Asplin, I.; Baer, P.; Brown, H. R.; Jones, S. A.; Henke, B.; Sauls, H.; Wolfe, S.; Morris, D. C.; Mcdonnell, D. P. Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen-Receptor Ligand, Provides Insights into the Role of Estrogen-Receptor in Bone. Endocrinology (Baltimore) 1997, 138, 3901-3911.
16. Wilson, S.; Ruenitz, P. C.; Ruzicka, J. A. Estrogen Receptor Affinity and Effects on MCF-7 Cell Growth of Triarylethylene Carboxylic Acids Related to Tamoxifen. J. Steroid Biochem. Mol. Biol. 1992, 42, 613-616.
17. Ruenitz, P. C.; Bourne, C. S.; Sullivan, K. J.; Moore, S. A. Estrogenic Triarylethylene Acetic Acids: Effect of Structural Variation on Estrogen Receptor Affinity and Estrogenic Potency and Efficacy in MCF-7 Cells. J. Med. Chem. 1999, 39, 4853-4859.
18. Ruenitz, P. C.; Shen, Y.; Li, M.; Liang, H.; Whitehead, Jr., R. D.; Pun, S.; Wronski, T. J. Specific Bone-Protective Effects of Metabolites/Derivatives of Tamoxifen and Clomiphene in Ovariectomized Rats. Bone 1998, 23, 537-542.
19. Ruenitz, P. C.; Bagley, J. R.; Mokler, C. M. Estrogenic and Antieatrogenic Activity of Monophenolic Analogues of Tamoxifen, (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. J. Med. Chem. 1982, 25, 1056-1060.
20. (a) Lednicer, D.; Lyster, S. C.; Duncan, G. W. Mammalian Antifertility Agents. IV. Basic 3,4-Dihydronaphthalenes and 1,2,3,4-Tetrahydro-1-naphthols. J. Med. Chem. 1967, 10, 78-84.
21. (b) Baumann, R. J.; Bush, T. L.; CrossDorsen, D. E.; Cashman, E. A.; Wright, P. S.; Zwolshen, J. H.; Davis, G. F.; Matthews, D. P.; Bender, D. M.; Bitonti, A. J. Clomiphene Analogues with Activity in Vitro and in Vivo Against Human Breast Cancer Cells. Biochem. Pharmacol. 1998, 55, 841-851.
22. Coe, P. L.; Scrivan, C. E. Crossed Coupling of Functionalized Ketones by Low Valent Titanium (The McMurry Reaction): a New Stereoselective Synthesis of Tamoxifen. J. Chem. Soc., Perkin Trans. 1 1986, 475-477.
23. (b) Gauthier, S.; Mailhot, J.; Labrie, F. New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction. J. Org. Chem. 1996, 61, 3890-3893.
24. (a) Bedford, G. R.; Richardson, D. N. Preparation and Identification of Cis and Trans Isomers of a Substituted Triarylethylene. Nature (London) 1968, 212, 733-734.
25. (b) Kilbourn, B. T.; Owston, P. G. Crystal Structure of the Hydrobromide of 1-p-(2-Dimethylaminoethoxyphenyl)-1,2-cis-diphenylbut-1-ene, a Compound with Oestrogenic Activity. J. Chem. Soc. B 1970, 1-5.
26. McCague, R.; Leclercq, G. Synthesis, Conformational Considerations, and Estrogen Receptor Binding of Diastereomers and Enantiomers of 1-[4-[2-(Dimethylamino)ethoxy]phenyl]-1,2-diphenylbutane (Dihydrotamoxifen). J. Med. Chem. 1987, 30, 1761-1767.
27. (a) Therberge, R.; Paul, G. J. C.; Bertrand, M. J. Systematic Study of the Effects of Experimental Parameters on the Beam-Induced Dehalogenation of Chlorpromazine in Liquid Secondary-Ion Mass-Spectrometry. Org. Mass Spectrom. 1994, 29, 18-25.
28. (b) Therberge, R.; Bertrand, M. J. Beam-Induced Dehalogenation in LSIMS - Effect of Halogen Type and Matrix Chemistry. J. Mass Spectrom. 1995, 1, 163-171.
29. Ruenitz, P. C.; Moore, S. A.; Kraft, K. S.; Bourne, C. S. Estrogenic Tamoxifen Derivatives: Categorization of Intrinsic Estrogenicity in MCF-7 Cells. J. Steroid Biochem. Mol. Biol. 1997, 63, 203-209.
30. Skidmore, J. R.; Walpole, A. L.; Wopdburn, J. Effect of Some Triphenylethylenes on Oestradiol Binding in Vitro to Macromolecules from Uterus and Anterior Pituitary. J. Endocrinol. 1972, 52, 289-298.
31. Ganesan, S.; Bashirelahi, N.; Young, J. D.; Cohen, S. P. Phenylmethylsulfonyl Fluoride (PMSF) Inhibits 17β-estradiol Binding to Estrogen Receptor from Human Prostate. Life Sci. 1987, 41, 2767-2776.
32. Ruenitz, P. C. Female Sex Hormones and Analogues. In Burger's Medicinal Chemistry, 5th ed.; Wolff, M. E., Ed.; Wiley: New York, 1997; Vol. 4, Chapter 57, pp 569-574.
33. (a) Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Häggblad, J.; Nilsson, S.; Gustafsson, J.-Å. Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors a and β. Endocrinology (Baltimore) 1997, 138, 863-870.
34. (b) Petersen, D. N.; Tkalcevic, G. T.; KozaTaylor, P. H.; Turi, T. G.; Brown, T. A. Identification of Estrogen Receptor Beta(2), a Functional Variant of Estrogen Receptor Beta Expressed in Normal Rat Tissues. Endocrinology (Baltimore) 1998, 139, 1082-1092.
35. Watanabe, T.; Inoue, S.; Ogawa, S.; Ishii, Y.; Hiroi, H.; Ikeda, K.; Orimo, A.; Muramatsu, M. Agonistic Effect of Tamoxifen Is Dependent on Cell-Type, ERE-promoter Context, and Estrogen-Receptor Subtype - Functional Difference Between Estrogen-Receptor-Alpha and Receptor-Beta. Biochem. Biophys. Res. Commun. 1997, 236, 140-145.
36. (a) Bocchinfuso, W. P.; Korach, K. S. Estrogen-Receptor Residues Required for Stereospecific Ligand Recognition and Activation. Mol. Endocrinol. 1997, 11, 587-594.
37. (b) Smith, C. L.; Nawaz, Z.; O'Malley, B. W. Coactivator and Corepressor Regulation of the Agonist/Antagonist Activity of the Mixed Antiestrogen, 4-Hydroxytamoxifen. Mol. Endocrinol. 1997, 11, 657-666.
38. (c) Castano, E.; Vorojeikina, D. P.; Notides, A. C. Phosphorylation of Serine-167 on the Human Estrogen-Receptor Is Important for Estrogen Response Element-Binding and Transcriptional Activation. Biochem. J. 1997, 326, 149-157.
39. (a) Frolik, C. A.; Bryant, H. U.; Black, E. C.; Magee, D. E.; Chandrasekhar, S. Time-Dependent Changes in Biochemical Bone Markers and Serum Cholesterol in Ovariectomized Rats: Effects of Raloxifene HCl, Tamoxifen, Estrogen, and Alendronate. Bone 1996, 18, 621-627.
40. (b) Ke, H. Z.; Chen, H. K.; Simmons, H. A.; Qi, H.; Crawford, D. T.; Pirie, C. M.; Chidsey-Frink, K. L.; Ma, Y. F.; Jee, W. S. S.; Thompson, D. D. Comparative Effects of Droloxifene, Tamoxifen, and Estrogen on Bone, Serum Cholesterol, and Uterine Histology in the Ovariectomized Rat Model. Bone 1997, 20, 31-39.